Emmecell Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EO2002 for the Treatment of Corneal Endothelial Disease

MENLO PARK, Calif.--(BUSINESS WIRE)--Emmecell receives FDA RMAT designation for EO2002, advancing development of its regenerative cell therapy for corneal endothelial disease.